Navigation Links
Repligen Reports Notice of Allowance of a United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
Date:4/30/2010

WALTHAM, Mass., April 30 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the United States Patent and Trademark Office has granted a Notice of Allowance of a patent covering the use of uridine in the treatment of patients with bipolar disorder.  The patent, which upon issue will remain in force until 2025 prior to any patent term extensions, covers the use of an effective dose of a uridine composition to improve one or more of the symptoms of bipolar disorder including depression, mania, mixed episodes, hypomania and anxiety.  Repligen is currently enrolling patients in a Phase 2b clinical trial of RG2417, an oral formulation of uridine, to assess its impact on the symptoms of acute depression.  This study is designed to confirm and extend the results of a Phase 2a study in which 6 weeks of treatment with RG2417 improved the symptoms of bipolar depression when compared to placebo as measured by the Montgomery-Asberg Depression Rating Scale.  Repligen has exclusively licensed this patent from McLean Hospital, the largest psychiatric facility of Harvard Medical School.

"We are very pleased with this action by the United States Patent Office covering the use of a potentially important new treatment for bipolar disorder," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation.  "This patent will provide commercial exclusivity for RG2417 in the United States through at least 2025."

This patent may qualify for up to 5 years of patent term extension under the provisions of the Hatch-Waxman Act, subject to certain limitations.  Foreign eq
'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
2. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
3. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
4. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
5. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
6. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
7. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
8. Capstone Reports Additional High Grade Copper-Gold Results From Minto East
9. Cardium Reports on Fourth Quarter and Year-End 2009 Financial Results and Recent Developments
10. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results
11. Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- CAS Medical Systems, Inc. (NASDAQ: CASM ) (CASMED), ... announced that Thomas M. Patton , President ... Annual Marcum MicroCap Conference on Thursday, May 30, 2013, ... City . The presentation is scheduled to ... and will be available via a live webcast at ...
(Date:5/23/2013)...  Omeros Corporation (NASDAQ: OMER ) ... (IND) to evaluate OMS824 in Huntington,s disease has ... Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), ... linked to a wide range of diseases that ... has shown promising results in animal models directly ...
(Date:5/23/2013)... , May 23, 2013  Echo Pharma Acquisition Limited ... waive down the Acceptance Threshold from 90 percent to ... Elan Share in accordance with the terms of the ... summarized below. Under the terms of the ... (NYSE: ELN ) for $12.50 per share ...
Breaking Medicine Technology:CASMED to Present at the 2nd Annual Marcum MicroCap Conference 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10
(Date:5/23/2013)... 23 (HealthDay News) -- A shortage of a critical ... across the United States to contain the spread of ... The drug, isoniazid (INH), was first used in 1951 ... the core of any first-line treatment for tuberculosis (TB). ... months, according to the U.S. Centers for Disease Control ...
(Date:5/23/2013)... have shown that an immune regulatory molecule called IL-21 ... viral infections. , The results are published in the ... how IL-21 could be important in the development of ... PhD, the first author of the paper. The senior ... Vaccine Center and a Georgia Research Alliance Eminent Scholar. ...
(Date:5/23/2013)... 2013 Netsmart today announced it ... of healthcare information technology (HIT) providers for 2013. , The ... of Healthcare Informatics magazine. Netsmart’s ranking of #49 ... strong continued growth is largely due to our commitment to ... of healthcare where resources are scarce, the demand for care ...
(Date:5/23/2013)... researchers examining outcomes for advanced heart-failure patients over ... with the increased availability and use of new ... death, caused by the rapid onset of severe ... However, the team found that even today, with ... more than three years after being diagnosed with ...
(Date:5/23/2013)... Elegance for a woman takes on so many ... her intrigue can often be found in the mystery of her ... soul is through her eyes. It is also true that ... is why the elegance of a woman can be found in ... more than any other time, utilize eyewear to not only compliment ...
Breaking Medicine News(10 mins):Health News:Shortage of Key Drug Hampering U.S. Efforts to Control TB: Report 2Health News:Vaccine blackjack: IL-21 critical to fight against viral infections 2Health News:Netsmart Named to Healthcare Informatics Top 100 List 2Health News:Death rates decline for advanced heart failure patients, but outcomes are still not ideal 2Health News:Death rates decline for advanced heart failure patients, but outcomes are still not ideal 3Health News:Dolabany Eyewear Adds Feminine Flare to Women's Designer Eyewear with 2013 New Release of Adelina by Best Image Optical, Inc. 2
... James S. Forrester, M.D., former chief of the ... the 2009 Lifetime Achievement Award from the American College ... March 29. , Currently the George Burns ... Forrester came to the medical center in 1969 as ...
... These new insights represent an important contribution to future ... prestigious science journal Nature and will be ... molecular mechanisms of hematopoiesis, which will take place in ... findings on the molecular mechanisms of blood formation (hematopoiesis) ...
... Overestimate Amount of Time it Takes to Form a New ... to Achieving Healthier HabitsGREENWICH, Conn., April 1 ... Nestle(R) Pure Life (R) brand bottled water, the number one ... think it takes six months or longer to form a ...
... PALM BEACH GARDENS, Fla., April 1 As ... http://www.silvercensus.com ), a national web ... announced today that it is urging American Veterans ... entitlement from the Veterans Administration called "Aid and ...
... Mass., April 1, EnVivo Pharmaceuticals today ... Corporation (MTPC) for the development and commercialization ... Japan and several other Asian countries. EVP-6124 ... agonist currently in development for cognition enhancement ...
... April 1 Immunotech Laboratories, Inc. Immunotech Laboratories ... in Puerto Rico with its abstract " Irreversible ... specific novel cytokine stimulation in vitro investigation of ... at the 5th European Conference on Clinical and ...
Cached Medicine News:Health News:ACC presents lifetime achievement award to Cedars-Sinai Heart Institute's James Forrester, M.D. 2Health News:Last step leading to blood cell formation elucidated 2Health News:Video: New Survey Reveals Misconceptions About Forming New Habits 2Health News:Video: New Survey Reveals Misconceptions About Forming New Habits 3Health News:Video: New Survey Reveals Misconceptions About Forming New Habits 4Health News:Little-Known VA Care Entitlement for Veterans Highlighted by SilverCensus.com 2Health News:Little-Known VA Care Entitlement for Veterans Highlighted by SilverCensus.com 3Health News:EnVivo and Mitsubishi Tanabe Enter License Agreement on EVP-6124 in Japan, Korea, Taiwan and Other Asian Countries 2Health News:EnVivo and Mitsubishi Tanabe Enter License Agreement on EVP-6124 in Japan, Korea, Taiwan and Other Asian Countries 3Health News:Beating a Global Killer: HIV/AIDS 2Health News:Beating a Global Killer: HIV/AIDS 3Health News:Beating a Global Killer: HIV/AIDS 4
...
The Doro Halo retractor system is designed for all neurosurgical applications where retraction of the brain tissue and an armrest is required....
Codman periosteal elevators, sharp, length 8" (203 mm), blade width 3/16" (5 mm)....
Hoen periosteal elevators, No.3, blade width 3/4" (20 mm), total length 7 1/2" (191 mm)....
Medicine Products: